erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer

1998653 citationsJournal Article

Authors

These data support the hypothesis of a preferential benefit from doxorubicin in patients with erbB-2-positive breast cancer.

Good health and well-being

Published in: JNCI Journal of the National Cancer Institute

Volume 90, Issue 18, pp. 1361-1370

Field-Weighted Citation Impact: 24.38